Robin Liang
PhD student at TREC
Cancer patients have a high risk of developing venous thromboembolism (VTE), especially in the first 6 months after diagnosis. The risk of VTE can be greatly reduced using anticoagulants to prevent thrombosis, but this treatment brings a high risk of bleeding. This makes it difficult to determine whose risk of thrombosis is greater than the risk of bleeding. Though there are several models that are used in the clinics to predict which cancer patients are likely to benefit from anticoagulation, their accuracy has been disputed. Ingrid Pabinger and colleagues set out to create and validate a clinical prediction model to predict VTE over 6 months in cancer patients.









